Dr. Stein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
161 Fort Washington Ave
Fl 9
New York, NY 10032Phone+1 212-305-5874Fax+1 212-305-6762
Summary
- Dr. Mark Stein is an oncologist in New York, NY and is affiliated with Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center/New York–Presbyterian Hospital. He received his medical degree from New York Medical College and has been in practice 19 years. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for cancer
Education & Training
- New York Medical CollegeClass of 1998
Certifications & Licensure
- FL State Medical License 2021 - Present
- NJ State Medical License 2004 - 2025
- NY State Medical License 1999 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Start of enrollment: 2009 Jun 01
- A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Start of enrollment: 2023 Sep 20
Roles: Contact
Publications & Presentations
PubMed
- 992 citationsTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch
Journal of Clinical Oncology. 2016-09-27 - 340 citationsPhase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell CarcinomaToni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea L. Harzstark
Journal of Clinical Oncology. 2013-01-10 - 223 citationsContemporary risk profile of prostate cancer in the United StatesYu-Hsuan Shao, Kitaw Demissie, Weichung Shih, Amit R. Mehta, Mark N. Stein
Journal of the National Cancer Institute. 2009-09-16
Press Mentions
- Study Sheds Light on Diabetes Drug for Prostate CancerNovember 8th, 2023
- Common Diabetes Drug Metformin Really Can Fight Certain CancersNovember 10th, 2023
- Can Metformin Delay Progression of Prostate Cancer? Study Provides InsightsNovember 11th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: